Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Change in Accured Expenses (2020 - 2025)

Journey Medical's Change in Accured Expenses history spans 6 years, with the latest figure at $6.4 million for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 349.82% year-over-year to $6.4 million, compared with a TTM value of $10.1 million through Dec 2025, up 446.97%, and an annual FY2025 reading of $10.1 million, up 446.97% over the prior year.
  • Change in Accured Expenses for Q4 2025 was $6.4 million at Journey Medical, up from $3.8 million in the prior quarter.
  • The five-year high for Change in Accured Expenses was $14.3 million in Q2 2021, with the low at -$10.5 million in Q3 2021.
  • Average Change in Accured Expenses over 5 years is $424050.0, with a median of $35500.0 recorded in 2022.
  • Biggest YoY gain for Change in Accured Expenses was 35681.82% in 2023; the steepest drop was 8643.75% in 2023.
  • Tracing DERM's Change in Accured Expenses over 5 years: stood at -$2.1 million in 2021, then surged by 101.65% to $35000.0 in 2022, then tumbled by 37.14% to $22000.0 in 2023, then surged by 6340.91% to $1.4 million in 2024, then soared by 349.82% to $6.4 million in 2025.
  • Per Business Quant, the three most recent readings for DERM's Change in Accured Expenses are $6.4 million (Q4 2025), $3.8 million (Q3 2025), and -$5.6 million (Q2 2025).